Exheus successfully completes capital increase and prepares for international market entry
Exheus, a spin-off of the UPC, the Sant Pau Hospital Research Institute (IIB Sant Pau), Summit SL and Mobile World Capital Barcelona’s innovation programme The Collider, has raised 900,000 euros. The investment will help to reach new European markets, establish a new commercial structure for international promotion and develop a new digital platform.
Feb 07, 2023
As a result of Exheus’ participation in the Decelera Menorca programme, Decelera Ventures I FCR was the operation’s lead investor, with WA4STEAM, NEXT GEN VENTURE A I, SCP and NEXT GEN VENTURE C I, SCP and more than a hundred business angels through Capital Cell, which resulted in a 650,000 euros fund raise. This was complemented by another 250,000 euros from the Centre for the Development of Industrial Technology (CDTI), which is part of the Spanish Ministry of Science and Innovation and promotes innovation and technological development of Spanish companies.
In addition to these 900,000 euros, Exheus was granted further 50,000 euros by EIT Health, a European organisation that aims to promote innovation in health and to accelerate entrepreneurship and innovation.
The funding will help Exheus to expand into European markets, create a commercial structure to access health systems of niche countries and work on the legal requirements necessary to operate internationally. Exheus also plans a B2B-focused digitalisation of the product developing a digital, automated and interactive platform, which would allow doctors and physicians to directly access and assess patients’ RNA test results.
“Our efforts during the last two years have helped us to develop the world’s most advanced health report. This capital increase will allow us to continue building the future of Exheus and promote personalised medicine, both in Spain and other European markets, always focusing on improving the lives of patients,” says Exheus CEO Teresa Tarragó.
A unique RNA test in the world
Exheus was born as a spin-off of the Complex Disease Genomics research group of the Sant Pau Hospital Research Institute (IIB Sant Pau), the Biomedical Engineering Research Centre (CREB) of the Universitat Politècnica de Catalunya-BarcelonaTech (UPC), Summit SL and Mobile World Capital Barcelona’s innovation programme The Collider, which fosters technology transfer between science, market and society.
Exheus analyses gene expression from blood transcriptomes to detect and correct abnormalities that affect a patient’s health. Today, Exheus is the world’s most sophisticated commercial RNA analysis technology. It makes it possible for health professionals to offer personalised recommendations.
